Laura J. Zitella

Laura J. Zitella,

MS, RN, ACNP-BC, AOCN

Laura J. Zitella

Laura J. Zitella,

MS, RN, ACNP-BC, AOCN

Nurse Practitioner, Associate Clinical Professor, University of California San Francisco

Laura J. Zitella,

MS, RN, ACNP-BC, AOCN

Nurse Practitioner, Associate Clinical Professor, University of California San Francisco

Laura J. Zitella is a nurse practitioner in the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program and Associate Clinical Professor in the Department of Physiological Nursing at the University of California San Francisco. She earned her Master of Science from the University of Illinois in Chicago and holds certifications as an acute care nurse practitioner and an advanced oncology certified nurse.

Her clinical expertise includes patients with hematologic malignancies receiving chemotherapy, immunotherapy, targeted therapy, investigational agents, hematopoietic cell transplantation, and supportive care. She is a prominent educator who has delivered hundreds of educational presentations to national and international audiences and authored numerous peer-reviewed publications, web courses, videos, and book chapters. Laura co-edited the Hematologic Malignancies in Adults textbook, which was awarded an American Medical Writers Association Medical Book Award Honorable Mention.

Laura is actively involved with the Advance Practice Provider Oncology Summit, Advanced Practitioner Society for Hematology and Oncology, the Oncology Nursing Society, and the CLL Society. She serves on medical advisory board of the CLL Society, the Journal of Advanced Practitioner in Oncology editorial board, and several oncology conference planning committees. She is the proud recipient of the ONS Excellence in Medical Oncology award, the DAISY award, and the inaugural Stanford Health Care Advanced Practice Provider of the Year award.

Laura's Shared Resources

Infection Risk Management in Multiple Myeloma: IMWG Guidelines for Prevention and Prophylaxis

Patients with multiple myeloma (MM) face a high risk of infections, particularly in the early stages of diagnosis and during treatment....
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Improving Diagnosis and Outcomes in Multiple Myeloma: Early Detection and Healthcare Disparities

Multiple myeloma (MM) is a hematologic malignancy that impacts plasma cells in the bone marrow, causing symptoms such as bone lesions, renal injury, anemia, and hypercalcemia....
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Early Daratumumab Monotherapy Delays Progression in High-Risk Smoldering Myeloma

Researchers of the phase 3 Aquila study presented at the 66th ASH Annual Meeting and showed that daratumumab (D) monotherapy significantly delays progression in patients with high-risk smoldering multiple myeloma...
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Provided by an unrestricted grant from

Provided by an unrestricted grant from

Share